$0.410
-0.010 (-2.38%)終値時点
- High
- 0.425
- Open
- 0.413
- VWAP
- 0.41
- Vol
- 259.33K
- Mkt Cap
- —
- Low
- 0.404
- Amount
- 107.07K
- EV/EBITDA, TTM
- 0.00
Knorex Ltd. is a Business to Business (B2B) technology company. The Company is specialized in providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its flagship product, Knorex XPO, is a self-service enterprise-grade cloud platform with a comprehensive suite of advertising management and execution (AMX) applications.
AI analysis of Knorex Ltd (KNRX)
sellGiven the current price of 0.41 and a staggering year-to-date change of -70.72%, KNRX is not a good buy right now. The company has also failed to file its annual report on time, which raises compliance concerns. Furthermore, the forward P/E is 0, indicating no earnings expectations, and the gross margin is declining, projected at 41.79% for Q4 2024. The main risk is the compliance issue with NYSE, which could lead to suspension or delisting if not resolved by November 2026.
バリュエーション指標
イベントタイムライン
ニュース
9.508-21NewsfilterKNOREX Releases 2025 Financial Statements with Going Concern Emphasis
8.508-19NewsfilterKNOREX Successfully Lists on NYSE American, Driving AI Growth
7.005-22seekingalphaKNOREX Fails to File Annual Report on Time
8.504-29NewsfilterKNOREX Launches AI Advertising Optimization Tools
2.002-23BenzingaVanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
KNRX FAQ — answered by Alphio AI
Knorex Ltd. is a Business to Business (B2B) technology company. The Company is specialized in providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its flagship product, Knorex XPO, is a self-service enterprise-grade cloud platform with a comprehensive suite of advertising management and execution (AMX) applications. It operates in the Technology sector.
Given the current price of 0.41 and a staggering year-to-date change of -70.72%, KNRX is not a good buy right now. The company has also failed to file its annual report on time, which raises compliance concerns. Furthermore, the forward P/E is 0, indicating no earnings expectations, and the gross margin is declining, projected at 41.79% for Q4 2024. The main risk is the compliance issue with NYSE, which could lead to suspension or delisting if not resolved by November 2026.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。